• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC - GALWAY PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM; STENT, CORONARY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC - GALWAY PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM; STENT, CORONARY, DRUG-ELUTING Back to Search Results
Model Number UNK340
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Dyspnea (1816); Myocardial Infarction (1969); Occlusion (1984); Numbness (2415)
Event Date 12/18/2015
Event Type  Injury  
Manufacturer Narrative
Device is a combination product.Device evaluated by mfr: it is indicated that the device will not be returned for evaluation.A review of the batch history, historical trending, and similar complaint trending review for the product family will be conducted.If there is any further relevant information from that review, a supplemental medwatch will be filed.(b)(4).
 
Event Description
Same case as mdr id 2134265-2016-01333 and 2134265-2016-01337.Platinum diversity clinical study.It was reported that myocardial infarction (mi) and stent occlusion occurred.In (b)(6) 2015, the patient underwent an urgent percutaneous coronary intervention.Target lesion #1 was a de novo lesion located in the distal right coronary artery (rca) with 99% stenosis.It was 20mm long, with a reference vessel diameter of 2.5mm.The lesion was located within or distal to a >60 degree bend in the vessel.The thrombolysis in mi (timi) flow was unknown.Target lesion #1 was treated with pre-dilatation of a 2.0mm balloon at 12 atmospheres and insertion of a 2.25x32 mm promus premier everolimus-eluting platinum chromium coronary stent.Post dilatation was performed with a 2.5mm balloon at 20 atmospheres.Post procedural residual stenosis was 0%.The thrombolysis in mi (timi) flow was 3.Target lesion #2 was treated with pre-dilatation of a 2.0mm balloon at 12 atmospheres and insertion a 2.50x16mm promus premier everolimus-eluting platinum chromium coronary stent.Post dilatation was performed with a 2.5mm balloon at 20 atmospheres.Post procedural residual stenosis was 0%.The thrombolysis in mi (timi) flow was 3.A percutaneous transluminal coronary angioplasty (ptca) of the posterior ventricular branch was performed through the previously placed stent in the distal rca.Due to vessel tortuosity, the physician was unable to advance the non bsc suture-mediated closure system to achieve right common femoral artery hemostasis.Therefore, the sheath was manually pulled post resolution of anticoagulation.Two days later, the patient was discharged on aspirin and clopidogrel.In (b)(6) 2015, the patient experienced an inferior/posterior mi.The patient presented with a 2-hour history of substernal chest pain, radiating to the jaw and bilateral hands, and associated with numbness in the fingers and shortness of breath.Per the paramedic, the pre-hospital electrocardiogram (ecg) did not show a st elevation myocardial infarction (stemi).The patient was taken directly to the cardiac catheterization lab.The patient underwent ptca with a 2.5x12mm non bsc balloon, followed by insertion of a 2.75x8mm non bsc drug eluting stent to the totally occluded proximal circumflex (cx) with no complications.Fever, due to possible early pneumonia, was treated with omnicef (cefotaxime) and doxycycline.There were no further symptoms.Four days later, the event was considered resolved and the patient was discharged on aspirin and plavix (clopidogrel).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PROMUS EVEROLIMUS ELUTING CORONARY STENT SYSTEM
Type of Device
STENT, CORONARY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC - GALWAY
Manufacturer (Section G)
BOSTON SCIENTIFIC - GALWAY
Manufacturer Contact
linda leimer
one scimed place
maple grove, MN 55311
7634941700
MDR Report Key5519755
MDR Text Key40962636
Report Number2134265-2016-02168
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
NA
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial
Report Date 02/25/2016
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/23/2016
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNK340
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/25/2016
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age54 YR
-
-